Malaria Prevention in Children: an Update

Overview

Journal Curr Opin Pediatr

Specialty Pediatrics

Date 2024 Feb 1

PMID 38299986

Authors

DeAnna J Friedman-Klabanoff

Dennis Adu-Gyasi

Kwaku Poku Asante

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Malaria cases and deaths decreased from 2000 to 2015 but remain increased since 2019. Several new developments and strategies could help reverse this trend. The purpose of this review is to discuss new World Health Organization (WHO) guidelines and recent research on malaria prevention in children.

Recent Findings: Fifteen countries have now rolled out seasonal malaria chemoprophylaxis (SMC) in children at highest risk for severe malaria, and new WHO recommendations provide more flexibility for SMC implementation in terms of target age groups, geographic region, and number of cycles. Recent studies confirm that malaria burden in school aged children, and their contribution to transmission, is high. New guidelines permit expanded chemoprevention options for these children. Two vaccines have been approved for use in malaria endemic countries, RTS,S/AS01 E and R21/Matrix-M. Additionally, pyrethroid-chlorfenapyr bed nets are being deployed to combat resistant mosquitoes.

Summary: While challenges remain in malaria control towards elimination, new guidelines and recently approved vaccines offer hope. Monitoring for continued vaccine and chemoprevention effectiveness, and for possible epidemiologic shifts in severe malaria presentation and deaths as additional prevention efforts roll out will be paramount.

References

Asmare G . Willingness to accept malaria vaccine among caregivers of under-5 children in Southwest Ethiopia: a community based cross-sectional study. Malar J. 2022; 21(1):146. PMC: 9097094. DOI: 10.1186/s12936-022-04164-z. View

Abdulraheem M, Ernest M, Ugwuanyi I, M Abkallo H, Nishikawa S, Adeleke M . High prevalence of Plasmodium malariae and Plasmodium ovale in co-infections with Plasmodium falciparum in asymptomatic malaria parasite carriers in southwestern Nigeria. Int J Parasitol. 2021; 52(1):23-33. DOI: 10.1016/j.ijpara.2021.06.003. View

Adjei M, Kubio C, Buamah M, Sarfo A, Suuri T, Ibrahim S . Effectiveness of seasonal malaria chemoprevention in reducing under-five malaria morbidity and mortality in the Savannah Region, Ghana. Ghana Med J. 2023; 56(2):64-70. PMC: 10336463. DOI: 10.4314/gmj.v56i2.2. View

Mahamar A, Sumner K, Levitt B, Freedman B, Traore A, Barry A . Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali. Malar J. 2022; 21(1):39. PMC: 8822718. DOI: 10.1186/s12936-022-04059-z. View

Dicko A, Ouedraogo J, Zongo I, Sagara I, Cairns M, Yerbanga R . Seasonal vaccination with RTS,S/AS01 vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 2023; 24(1):75-86. DOI: 10.1016/S1473-3099(23)00368-7. View

Collins K, Snaith R, Cottingham M, Gilbert S, Hill A . Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017; 7:46621. PMC: 5395940. DOI: 10.1038/srep46621. View

Datoo M, Natama H, Some A, Bellamy D, Traore O, Rouamba T . Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022; 22(12):1728-1736. DOI: 10.1016/S1473-3099(22)00442-X. View

Lyke K, Berry A, Mason K, Idris A, OCallahan M, Happe M . Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial. Lancet Infect Dis. 2023; 23(5):578-588. PMC: 10121890. DOI: 10.1016/S1473-3099(22)00793-9. View

van der Boor S, Smit M, van Beek S, Ramjith J, Teelen K, van de Vegte-Bolmer M . Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet Infect Dis. 2022; 22(11):1596-1605. PMC: 9605874. DOI: 10.1016/S1473-3099(22)00428-5. View

10.

Regules J, Cicatelli S, Bennett J, Paolino K, Twomey P, Moon J . Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. J Infect Dis. 2016; 214(5):762-71. DOI: 10.1093/infdis/jiw237. View

11.

Agaba B, Rugera S, Mpirirwe R, Atekat M, Okubal S, Masereka K . Asymptomatic malaria infection, associated factors and accuracy of diagnostic tests in a historically high transmission setting in Northern Uganda. Malar J. 2022; 21(1):392. PMC: 9783970. DOI: 10.1186/s12936-022-04421-1. View

12.

Datoo M, Natama M, Some A, Traore O, Rouamba T, Bellamy D . Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021; 397(10287):1809-1818. PMC: 8121760. DOI: 10.1016/S0140-6736(21)00943-0. View

13.

Neafsey D, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A . Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med. 2015; 373(21):2025-2037. PMC: 4762279. DOI: 10.1056/NEJMoa1505819. View

14.

Amin M, Afrin S, Bonna A, Rozars M, Nabi M, Hawlader M . Knowledge and acceptance of malaria vaccine among parents of under-five children of malaria endemic areas in Bangladesh: A cross-sectional study. Health Expect. 2023; 26(6):2630-2643. PMC: 10632622. DOI: 10.1111/hex.13862. View

15.

Boyce R, Muhindo E, Baguma E, Muhindo R, Shem B, Francois R . Permethrin-treated baby wraps for the prevention of malaria: results of a randomized controlled pilot study in rural Uganda. Malar J. 2022; 21(1):63. PMC: 8864600. DOI: 10.1186/s12936-022-04086-w. View

16.

Wu R, Idris A, Berkowitz N, Happe M, Gaudinski M, Buettner C . Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. N Engl J Med. 2022; 387(5):397-407. PMC: 9806693. DOI: 10.1056/NEJMoa2203067. View

17.

Sagara I, Healy S, Assadou M, Kone M, Swihart B, Kwan J . Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. Lancet Infect Dis. 2023; 23(11):1266-1279. PMC: 10615700. DOI: 10.1016/S1473-3099(23)00276-1. View

18.

Yeboah D, Owusu-Marfo J, Agyeman Y . Predictors of malaria vaccine uptake among children 6-24 months in the Kassena Nankana Municipality in the Upper East Region of Ghana. Malar J. 2022; 21(1):339. PMC: 9666942. DOI: 10.1186/s12936-022-04378-1. View

19.

Tiono A, Palacpac N, Bougouma E, Nebie I, Ouedraogo A, Houard S . infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children. Front Immunol. 2023; 14:1119820. PMC: 10040972. DOI: 10.3389/fimmu.2023.1119820. View

20.

Maiteki-Sebuguzi C, Gonahasa S, Kamya M, Katureebe A, Bagala I, Lynd A . Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign. Lancet Infect Dis. 2022; 23(2):247-258. DOI: 10.1016/S1473-3099(22)00469-8. View